valproic acid has been researched along with tolbutamide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Hanano, M; Iga, T; Sawada, Y; Sugiyama, Y | 1 |
| Hirvisalo, EL; Kannisto, H; Neuvonen, PJ | 1 |
| Backman, JT; Kivistö, KT; Neuvonen, PJ; Wang, JS; Wen, X | 1 |
| Feng, R; Mandula, H; Parepally, JM; Smith, QR | 1 |
| Huang, HH; Lin, LH; Zhang, P; Zhong, DF | 1 |
| Bekersky, I; Blum, RA; Tolbert, D; Walzer, M | 1 |
| Dezaki, K; Kakei, M; Maejima, Y; Manaka, K; Nakata, M; Rita, RS; Shimomura, K; Yada, T; Yoshida, M | 1 |
2 review(s) available for valproic acid and tolbutamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.
Topics: Animals; Antipyrine; Barbiturates; Biological Availability; Chlorpromazine; Diazepam; Drug Evaluation; Female; Half-Life; Humans; Kinetics; Male; Metabolic Clearance Rate; Pentazocine; Pharmaceutical Preparations; Phenylbutazone; Phenytoin; Propranolol; Quinidine; Rats; Species Specificity; Tissue Distribution; Tolbutamide; Valproic Acid; Warfarin | 1985 |
1 trial(s) available for valproic acid and tolbutamide
| Article | Year |
|---|---|
Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Topics: Adolescent; Adult; Anticonvulsants; Area Under Curve; Benzodiazepines; Caffeine; Central Nervous System Stimulants; Clinical Trials, Phase I as Topic; Clobazam; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Hypoglycemic Agents; Isoenzymes; Lamotrigine; Male; Midazolam; Middle Aged; Models, Statistical; Pharmacokinetics; Prospective Studies; Tolbutamide; Triazines; Valproic Acid; Young Adult | 2012 |
20 other study(ies) available for valproic acid and tolbutamide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effect of activated charcoal on absorption of tolbutamide and valproate in man.
Topics: Adult; Charcoal; Female; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Middle Aged; Solubility; Tolbutamide; Valproic Acid | 1983 |
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxylation; Isoenzymes; Microsomes, Liver; Mixed Function Oxygenases; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Time Factors; Tolbutamide; Valproic Acid | 2001 |
Role of site-specific binding to plasma albumin in drug availability to brain.
Topics: Animals; Binding, Competitive; Biological Availability; Brain; Ibuprofen; Male; Perfusion; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley; Serum Albumin; Tolbutamide; Ultrafiltration; Valproic Acid; Warfarin | 2006 |
[The inhibition of CYP2C9 isoenzyme in Cunninghamella blakesleeana AS 3. 910].
Topics: Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Catalysis; Chromatography, High Pressure Liquid; Cunninghamella; Cytochrome P-450 CYP2C9; Diclofenac; Dose-Response Relationship, Drug; Drug Interactions; Fungal Proteins; Indomethacin; Isoenzymes; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulfaphenazole; Tolbutamide; Valproic Acid | 2006 |
Chronic exposure to valproic acid promotes insulin release, reduces KATP channel current and does not affect Ca (2+) signaling in mouse islets.
Topics: Animals; Calcium Signaling; Insulin; Islets of Langerhans; KATP Channels; Male; Mice; Models, Animal; Patch-Clamp Techniques; Potassium Channel Blockers; Tolbutamide; Valproic Acid | 2014 |